Skip to Main Content

Illumina Inc

ILMN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of ILMN by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb 10, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Jan 29, 2026
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 31, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jun 09, 2025
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 01, 2025
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 01, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 25, 2025
Michael C. Burgess House / R Sale $15,001 - $50,000 Sep 03, 2024
Michael C. Burgess House / R Sale $15,001 - $50,000 Aug 30, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Jul 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 May 29, 2024
Ro Khanna House / D Sale $1,001 - $15,000 May 28, 2024
Thomas H. Kean, Jr. House / R Purchase $1,001 - $15,000 Apr 19, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Mar 11, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Mar 11, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Feb 12, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Feb 12, 2024
Michael C. Burgess House / R Purchase $15,001 - $50,000 Feb 12, 2024
Michael C. Burgess House / R Purchase $1,001 - $15,000 Jan 02, 2024
Michael C. Burgess House / R Purchase $15,001 - $50,000 Jan 02, 2024
Michael C. Burgess House / R Sale $1,001 - $15,000 Jan 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 05, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Nov 03, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 31, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Aug 29, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 28, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Jun 29, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Jun 26, 2023
Ro Khanna House / D Sale $1,001 - $15,000 May 04, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Apr 10, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 14, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Feb 10, 2023
Ro Khanna House / D Sale $15,001 - $50,000 Dec 05, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 23, 2022
Ro Khanna House / D Sale $15,001 - $50,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 19, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 17, 2022
Kathy E. Manning House / D Sale $15,001 - $50,000 Jun 10, 2022
Ro Khanna House / D Sale $15,001 - $50,000 N/A
Ro Khanna House / D Sale $15,001 - $50,000 May 23, 2022
Ro Khanna House / D Sale $1,001 - $15,000 May 10, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 May 05, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 May 05, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 13, 2022
ILMN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ILMN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ILMN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in ILMN holdings by institutional investors

Quarterly net insider trading by ILMN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $320,000 Apr 20, 2026 Issue: Budget/Appropriations Health Issues Homeland Security Medicare/Medicaid Trade (domestic/foreign)
  • $330,000 Jan 20, 2026 Issue: None
  • $380,000 Oct 20, 2025 Issue: Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $410,000 Jul 21, 2025 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $620,000 May 08, 2025 Issue: Budget/Appropriations Health Issues Homeland Security
  • $400,000 Jan 21, 2025 Issue: Budget/Appropriations Health Issues Defense
  • $280,000 Dec 12, 2024 Issue: Budget/Appropriations Defense Health Issues
  • $270,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Health Issues
  • $510,000 Jan 22, 2024 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $420,000 Oct 20, 2023 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $1,460,000 Jul 20, 2023 Issue: Defense Trade (domestic/foreign) Government Issues Health Issues
  • $1,300,000 Jan 20, 2023 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,380,000 Oct 20, 2022 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,690,000 Jul 20, 2022 Issue: Trade (domestic/foreign) Government Issues Health Issues
  • $1,960,000 Apr 20, 2022 Issue: Government Issues Health Issues
  • $820,000 Jan 20, 2022 Issue: Government Issues
  • $10,000 Jan 20, 2022 Issue: Government Issues
  • $60,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: None
  • $40,000 Jan 20, 2022 Issue: Labor Issues/Antitrust/Workplace Medicare/Medicaid Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $60,000 Jan 19, 2022 Issue: Health Issues
  • $320,000 Jan 19, 2022 Issue: Health Issues Government Issues
  • $10,000 Oct 28, 2021 Issue: Government Issues
  • $920,000 Oct 21, 2021 Issue: Government Issues
  • $60,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Oct 20, 2021 Issue: None
  • $40,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Labor Issues/Antitrust/Workplace
  • $10,000 Oct 19, 2021 Issue: Government Issues
  • $50,000 Oct 19, 2021 Issue: Health Issues
  • $375,000 Oct 18, 2021 Issue: Health Issues Government Issues
  • $20,000 Jul 29, 2021 Issue: Health Issues
  • $60,000 Jul 20, 2021 Issue: Health Issues Labor Issues/Antitrust/Workplace
  • $40,000 Jul 20, 2021 Issue: Labor Issues/Antitrust/Workplace Health Issues Veterans Medicare/Medicaid
  • $40,000 Jul 20, 2021 Issue: Government Issues
  • $150,000 Jul 19, 2021 Issue: Health Issues Government Issues
  • $50,000 Jul 19, 2021 Issue: Trade (domestic/foreign)
  • $290,000 Apr 20, 2021 Issue: None
  • $270,000 Jan 21, 2021 Issue: None
  • $270,000 Oct 20, 2020 Issue: None
  • $170,000 Jul 20, 2020 Issue: None
  • $180,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: None
  • $160,000 Oct 21, 2019 Issue: Budget/Appropriations Health Issues
  • $160,000 Jul 22, 2019 Issue: Budget/Appropriations Health Issues
  • $130,000 Apr 22, 2019 Issue: Health Issues Budget/Appropriations
  • $60,000 Jan 22, 2019 Issue: Health Issues
  • $60,000 Oct 22, 2018 Issue: Health Issues
  • $70,000 Jul 20, 2018 Issue: Health Issues
  • $100,000 Apr 20, 2018 Issue: Medicare/Medicaid Budget/Appropriations
  • $50,000 Jan 19, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
  • $50,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
  • $50,000 Jul 20, 2017 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Medicare/Medicaid
  • $40,000 Apr 18, 2017 Issue: Medical/Disease Research/Clinical Labs
  • $45,000 Jan 13, 2017 Issue: Health Issues
  • $45,000 Oct 19, 2016 Issue: Health Issues
  • $60,000 Jul 20, 2016 Issue: Health Issues
  • $90,000 Apr 20, 2016 Issue: Health Issues
  • $20,000 Jan 20, 2016 Issue: Health Issues
  • $40,000 Jan 18, 2013 Issue: Homeland Security Science/Technology Defense

ILMN Estimated quarterly lobbying spending

ILMN Revenue by Segment or Geography

By Segment
By Geography
ILMN Income Statement
ILMN Balance Sheet
ILMN Cash Flow
U.S. Patents

New ILMN patent grants

  • Patent Title: Modified polymerases for improved incorporation of nucleotide analogues Sep. 19, 2017
  • Patent Title: Kinetic exclusion amplification of nucleic acid libraries Sep. 12, 2017
  • Patent Title: Polymer coatings Sep. 05, 2017
  • Patent Title: Compositions and methods for preparing oligonucleotide solutions Aug. 29, 2017
  • Patent Title: Compositions, systems, and methods for detecting events using tethers anchored to or adjacent to nanopores Jul. 18, 2017
  • Patent Title: Nucleic acid sample enrichment for sequencing applications Jul. 11, 2017
  • Patent Title: Compositions and methods for polynucleotide sequencing Jun. 27, 2017
  • Patent Title: Microfabrication methods for the optimal patterning of substrates Jun. 13, 2017
  • Patent Title: Polynucleotide modification on solid support Jun. 13, 2017
  • Patent Title: Modified polymerases for improved incorporation of nucleotide analogues Jun. 13, 2017
  • Patent Title: Microarray fabrication system and method Jun. 06, 2017
  • Patent Title: Haplotype resolved genome sequencing Jun. 06, 2017
  • Patent Title: Integrated optoelectronic read head and fluidic cartridge useful for nucleic acid sequencing May. 16, 2017
  • Patent Title: Methods and compositions for processing chemical reactions May. 16, 2017
  • Patent Title: Methods for selecting and amplifying polynucleotides Apr. 18, 2017
  • Patent Title: Tandem sequencing top and bottom strands of double stranded nucleic acid using arrays configured for single molecule detection Mar. 28, 2017
  • Patent Title: Functionalization and purification of molecules by reversible group exchange Mar. 21, 2017
  • Patent Title: Method of nucleic acid amplification Mar. 14, 2017
  • Patent Title: Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization Mar. 07, 2017
  • Patent Title: Sequencing by orthogonal synthesis Feb. 21, 2017
  • Patent Title: Solid-phase clonal amplification and related methods Feb. 21, 2017
  • Patent Title: Methods of nucleic acid sequencing Feb. 21, 2017
  • Patent Title: Array domains having rotated patterns Feb. 14, 2017
  • Patent Title: Optical alignment tool Jan. 10, 2017
  • Patent Title: Data processing system and methods Dec. 27, 2016
  • Patent Title: Gel patterned surfaces Dec. 06, 2016
  • Patent Title: Reducing adapter dimer formation Nov. 29, 2016
  • Patent Title: Formylpyrrole-based heterocycles for nucleic acid attachment to supports Oct. 25, 2016
  • Patent Title: Compositions and methods for nucleotide sequencing Oct. 18, 2016
  • Patent Title: Methods and compositions for nucleic acid sequencing Sep. 27, 2016
  • Patent Title: Cloud computing environment for biological data Sep. 13, 2016
  • Patent Title: Detection of nucleic acid reactions on bead arrays Sep. 13, 2016
  • Patent Title: Method of sequencing nucleic acid colonies formed on a surface by re-seeding Aug. 16, 2016
  • Patent Title: Compositions and methods for preparing oligonucleotide solutions Aug. 16, 2016
  • Patent Title: Devices and systems for creation of dna cluster arrays Aug. 16, 2016
  • Patent Title: Fluidic system for reagent delivery to a flow cell Aug. 09, 2016
  • Patent Title: Dynamic autofocus method and system for assay imager Aug. 02, 2016
  • Patent Title: Multiplex decoding of array sensors with microspheres Jul. 26, 2016
  • Patent Title: Flow cells for biological or chemical analysis Jul. 12, 2016
  • Patent Title: Compensator for multiple surface imaging Jun. 14, 2016
  • Patent Title: Selective enrichment of nucleic acids Jun. 14, 2016
  • Patent Title: Conformational probes and methods for sequencing nucleic acids May. 31, 2016
  • Patent Title: Flow cells and manifolds having an electroosmotic pump May. 24, 2016
  • Patent Title: Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization May. 17, 2016
  • Patent Title: Efficient biomolecule recycling method and system Apr. 26, 2016
  • Patent Title: Integrated sequencing apparatuses and methods of use Apr. 12, 2016
  • Patent Title: Methods of nucleic acid amplification and sequencing Mar. 29, 2016
  • Patent Title: Use of microfluidic systems in the detection of target analytes using microsphere arrays Mar. 22, 2016
  • Patent Title: Apparatus and methods for kinetic analysis and determination of nucleic acid sequences Mar. 08, 2016
  • Patent Title: Detection of nucleic acid reactions on bead arrays Mar. 08, 2016
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to ILMN from public contracts

ILMN News

Recent insights relating to ILMN

CNBC Recommendations

Recent picks made for ILMN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ILMN

ILMN Analyst Ratings

ILMN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ILMN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ILMN stock a Buy, Sell, or Hold?

  • What is the price target for $ILMN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ILMN Top Shareholders
Shareholder
Shares Held
ILMN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ILMN stock?

  • Who owns the most shares of $ILMN stock?

  • What funds own $ILMN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ILMN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ILMN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ILMN

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

  • Address San Diego, CA
  • Market Cap 25.3 billion
  • Employees 8,650
  • Industrial Classification Laboratory Analytical Instruments
Illumina Inc Executive Compensation
Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation